HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2+ breast cancer with brain metastases

Heather McArthur, MD, MPH, of Cedars-Sinai Medical Center, Los Angeles, CA, outlines the exploratory efficacy analyses in patients with brain metastases enrolled in the HER2CLIMB trial (NCT02614794), which evaluated tucatinib versus placebo in combination with capecitabine and trastuzumab in patients with advanced HER2+ breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).